MAZE THERAPEUTICS, INC. Defined Contribution Plan, Cost
MAZE THERAPEUTICS, INC. (MAZE) reported Defined Contribution Plan, Cost of $500.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-25
- MAZE THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2025 was $500.00K, a 25.00% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. defined contribution plan, cost for fiscal 2024 was $400.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-03-25 |
| 2024-12-31 | $400.00K 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |